Sign In
Buy MRTX
$58.70
+0 (+0%)
At Close: Apr 19, 2024
Mirati (MRTX) Up on FDA Nod to Adagrasib for KRAS Mutated NSCLC
07:32am, Tuesday, 13'th Dec 2022
The accelerated approval of Mirati Therapeutics' (MRTX) Krazati is based on ORR and DOR data from the phase II registration-enabling cohort of the KRYSTAL-1 study.
Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues
05:52pm, Monday, 12'th Dec 2022
Mirati won FDA approval for its rival to Amgen's lung cancer drug on Monday. The approval comes as MRTX stock continues to experience wild swings.
Why Mirati Therapeutics Shares Are Getting Hammered Again Today - Mirati Therapeutics (NASDAQ:MRTX)
11:35am, Thursday, 08'th Dec 2022
Mirati Therapeutics Inc MRTX shares are trading lower by 12.18% to $43.55 during Thursday's session after multiple analysts downgraded their ratings on the stock and lowered their price targets. Share
Why Shares of Mirati Therapeutics Fell Wednesday
04:28pm, Wednesday, 07'th Dec 2022
The company presented phase 2 data from its non-small cell lung cancer therapy.
Mirati (MRTX) Down After 1st-Line Lung Cancer Data on Adagrasib
12:02pm, Wednesday, 07'th Dec 2022
Mirati Therapeutics' (MRTX) preliminary data from the first-line NSCLC study showed that adagrasib plus Merck's Keytruda achieved an objective response rate of 49%.
Why Shares of Mirati Therapeutics Fell Tuesday
03:44pm, Tuesday, 06'th Dec 2022
Investors and analysts were unimpressed by trial results on the company's combination therapy to treat non-small cell lung cancer.
Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up
10:17am, Tuesday, 06'th Dec 2022
Mirati said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed on questions about its market opportunity. The post Mirati Therapeutics Crashes As The Cancer Rivalry W
Mirati's (MRTX) Stock Rallies 11% on Buyout Speculations
12:02pm, Thursday, 24'th Nov 2022
Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated KRASG12C-mutated NSCLC is under review with the FDA with a decis
Mirati Therapeutics, Inc. (MRTX) Q3 2022 - Earnings Call Transcript
10:27pm, Tuesday, 08'th Nov 2022
Mirati Therapeutics, Inc. (NASDAQ:MRTX ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Ryan Asay - Vice President of Corporate Affairs David Meek - Chief Executive
Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates
06:48pm, Tuesday, 08'th Nov 2022
Mirati (MRTX) delivered earnings and revenue surprises of 10.69% and 15.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
4 Biotech Stocks With Huge Incoming Catalysts
05:29am, Wednesday, 12'th Oct 2022
All four of these drugmakers are expecting important FDA approval decisions over the next few months.
Amgen Vs. Mirati: Playing To Win In KRAS Mutated Lung Cancer
01:36pm, Thursday, 15'th Sep 2022
Amgen's KRAS targeting drug Lumakras has now been approved in the US and Europe, making $77m sales in Q222. Mirati Therapeutics also has a KRAS targeting drug which may well win approval in December i
3 Stocks Expecting Good News From the FDA
07:37am, Monday, 12'th Sep 2022
Here are the upcoming catalysts for Mirati Therapeutics, Novavax, and Heron Therapeutics.
Cancer-Drug Maker's Solid Position And Successful Drug Record Drive Growth
05:09pm, Thursday, 08'th Sep 2022
Cancer-drug maker Amgen solidified its position in a highly competitive market by acquiring its rival Mirati Therapeutics.
Mirati: A Potential Blockbuster Stock, Will Need Patience
03:42pm, Thursday, 08'th Sep 2022
Mirati has strong competitive differences against larger rival Amgen. However, lead indication, 2nd line NSCLC, is not where these differences will come out.
